An oligonucleotide carrier based on β-1,3-glucans

Kazuo Sakurai, Seiji Shinkai

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.

Original languageEnglish
Title of host publicationNon-viral Gene Therapy
Subtitle of host publicationGene Design and Delivery
PublisherSpringer-Verlag Tokyo
Pages103-117
Number of pages15
ISBN (Electronic)9784431278795
ISBN (Print)4431251227, 9784431251224
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

Antisense DNA
Glucans
Static Electricity
Oligonucleotides
Cations
Hydrogen
Nucleotides
Electrostatic force
DNA
Complexation
Hydrogen bonds
Compaction

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sakurai, K., & Shinkai, S. (2005). An oligonucleotide carrier based on β-1,3-glucans. In Non-viral Gene Therapy: Gene Design and Delivery (pp. 103-117). Springer-Verlag Tokyo. https://doi.org/10.1007/4-431-27879-6_9

An oligonucleotide carrier based on β-1,3-glucans. / Sakurai, Kazuo; Shinkai, Seiji.

Non-viral Gene Therapy: Gene Design and Delivery. Springer-Verlag Tokyo, 2005. p. 103-117.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sakurai, K & Shinkai, S 2005, An oligonucleotide carrier based on β-1,3-glucans. in Non-viral Gene Therapy: Gene Design and Delivery. Springer-Verlag Tokyo, pp. 103-117. https://doi.org/10.1007/4-431-27879-6_9
Sakurai K, Shinkai S. An oligonucleotide carrier based on β-1,3-glucans. In Non-viral Gene Therapy: Gene Design and Delivery. Springer-Verlag Tokyo. 2005. p. 103-117 https://doi.org/10.1007/4-431-27879-6_9
Sakurai, Kazuo ; Shinkai, Seiji. / An oligonucleotide carrier based on β-1,3-glucans. Non-viral Gene Therapy: Gene Design and Delivery. Springer-Verlag Tokyo, 2005. pp. 103-117
@inbook{61068db21fc94179a9f0b5501fe1c99f,
title = "An oligonucleotide carrier based on β-1,3-glucans",
abstract = "6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.",
author = "Kazuo Sakurai and Seiji Shinkai",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/4-431-27879-6_9",
language = "English",
isbn = "4431251227",
pages = "103--117",
booktitle = "Non-viral Gene Therapy",
publisher = "Springer-Verlag Tokyo",

}

TY - CHAP

T1 - An oligonucleotide carrier based on β-1,3-glucans

AU - Sakurai, Kazuo

AU - Shinkai, Seiji

PY - 2005/1/1

Y1 - 2005/1/1

N2 - 6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.

AB - 6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.

UR - http://www.scopus.com/inward/record.url?scp=84920077573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920077573&partnerID=8YFLogxK

U2 - 10.1007/4-431-27879-6_9

DO - 10.1007/4-431-27879-6_9

M3 - Chapter

SN - 4431251227

SN - 9784431251224

SP - 103

EP - 117

BT - Non-viral Gene Therapy

PB - Springer-Verlag Tokyo

ER -